ABUS vs REG
Arbutus Biopharma Corp (ABUS) versus Regency Centers Corporation (REG) — a side-by-side from cached financials, not a winner call.
Arbutus Biopharma Corp (ABUS) is a biotechnology company listed on NASDAQ.
Regency Centers Corporation (REG) is a reit - retail company listed on US.
Latest reported ABUS revenue for 2024-12-31 was $6.2M. Net income was -$69.9M. Revenue was down 66.0% from 2023-12-31 to 2024-12-31. ABUS currently screens at market cap $883.0M and trailing P/E 5.4.
REG does not have a complete income-statement cache yet.
ABUS currently screens at market cap $883.0M and trailing P/E 5.4. REG currently screens at market cap $12.93B and trailing P/E 33.5.
Not investment advice. Open the ABUS and REG stock pages for the full models.
Not investment advice.